The clinical potentials of adjunctive fluvoxamine to clozapine treatment: a systematic review

  title={The clinical potentials of adjunctive fluvoxamine to clozapine treatment: a systematic review},
  author={C. Polcwiartek and J. Nielsen},
  • C. Polcwiartek, J. Nielsen
  • Published 2015
  • Medicine, Psychology
  • Psychopharmacology
  • RationaleNew clozapine optimization strategies are warranted, as some patients do not achieve sufficient response and experience various adverse effects. Fluvoxamine is a potent CYP1A2 inhibitor and may increase the ratio of clozapine to its primary metabolite N-desmethylclozapine (NDMC).ObjectivesThis study aims to review all pharmacodynamic effects and the adverse effect profile of changing the clozapine/NDMC ratio with adjunctive fluvoxamine.MethodsMEDLINE, Embase, and the Cochrane Library… CONTINUE READING
    Potential Role of Patients’ CYP3A-Status in Clozapine Pharmacokinetics
    • 14
    • PDF
    Comedication of Valproic Acid Is Associated With Increased Metabolism of Clozapine
    • 6
    Treatment of Clozapine Nonresponders
    • 1


    Publications referenced by this paper.
    Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances.
    • 103
    • Highly Influential
    Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients.
    • 86
    • Highly Influential
    Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study.
    • 141
    • Highly Influential
    Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial.
    • 62
    • Highly Influential
    Fluvoxamine Augmentation of Olanzapine in Chronic Schizophrenia: Pharmacokinetic Interactions and Clinical Effects
    • 59
    Nonresponse to Clozapine and Ultrarapid CYP1A2 Activity: Clinical Data and Analysis of CYP1A2 Gene
    • 106